Evaluation of fixed versus flexible GnRH antagonist protocols outcomes in controlled ovarian stimulation in polycystic ovary syndrome.
Not Applicable
- Conditions
- POLY CYSTIC OVARIAN SYNDROME.Sclerocystic ovary syndrome Stein-Leventhal syndrome
- Registration Number
- IRCT201101135181N5
- Lead Sponsor
- Tehran University of Medical SciencesVice-chancellor of research,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Inclusion criteria : infertile patients with poly cystic ovary syndrome;20-40 years old
Body mass index BMI 20-30 kg/m2
Exclusion criteria: endometriosis;ovarian cysts; pelvic neoplasia of the uterine and ovarian ; endocrine disorders (disorders of tyroid , prolactin); male factor infertility; blocked fallopian tubes in HSG, FSH levels on the 3th day of menestration >12miu/ml, previous OHSS; history of RIF (RECURRENT IMPLANTATION FAILURE)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical pregnancy rate. Timepoint: 4-6weeks after emberyo transfer. Method of measurement: the presence of gestational sac with fetal heart beat detectionat 6–7 weeks of gestation.
- Secondary Outcome Measures
Name Time Method Dose of cetrotide. Timepoint: at the end of controlled ovarian stimulation period. Method of measurement: dose of administration of Cetrotide.;Duration of administration of Cetrotide. Timepoint: at the end of controlled ovarian stimulation period. Method of measurement: days of administration of Cetrotide.;Ongoing pregnancy. Timepoint: the presence of gestational sac with fetal heart beat detection at 12 w of gestation. Method of measurement: the presence of gestational sac with fetal heart beat detection at 12 w of gestation.;Duration of administration of rFSH. Timepoint: at the end of controlled ovarian stimulation period. Method of measurement: days of administration of rFSH.;Dose of rFSH. Timepoint: at the end of controlled ovarian stimulation period. Method of measurement: dose of administration of rFSH.;Hospitalization rate due to OHSS. Timepoint: at the controlled ovarian stimulation period -UNTIL 4 weeks after pregnancy. Method of measurement: days of hospitalization due to OHSS.